Sterling Joshua, Garcia Maurice M
Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Division of Urology, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA, USA.
Transl Androl Urol. 2020 Mar;9(Suppl 2):S215-S226. doi: 10.21037/tau.2019.09.28.
Gender affirming medical and surgical treatments affect the reproductive potential of transgender individuals. Prior to the development of assisted reproductive technologies (ART), genital gender-affirming surgery frequently eliminated a patient's reproductive potential. Today, all patients should be counseled on their fertility preservation (FP) options before medical and surgical transition, yet this appears to seldom occur in practice. The following review is the result of a systematic literature search of PubMed, Medline and Google Scholar to identify current and future FP options, barriers to treatment patients face, practice patterns of transgender health care providers, and if there were any standardized counseling protocols. Options for transwomen at any point in their transition range from simply providing a semen sample to be used with assistive reproductive techniques to experimental techniques involving testicular cryopreservation followed by initiation of spermatogenesis. Transmen before and after starting hormone therapy can pursue any assistive reproductive techniques available for ciswomen. Future options currently under investigation include ovarian tissue cryopreservation (OTC) with oocyte maturation. In addition to counseling about their FP options, patients should be advised prospectively about the requirements, process details, the total costs associated with achieving pregnancy, and the inherent risks associated with using preserved genetic material including risk of failure, and maternal and fetal health risks. Transgender patients report using assistive reproductive services difficult, due to a lack of dialogue about fertility and the lack of information offered to them- presumably because their circumstances do not fit into a traditional narrative familiar to providers. Physicians and health care providers would benefit from better to help transgender patients make informed decisions and better about transgender patients in general, and FP options available to them.
性别肯定性医疗和手术治疗会影响跨性别者的生殖潜能。在辅助生殖技术(ART)发展之前,生殖器性别肯定性手术常常会消除患者的生殖潜能。如今,所有患者在进行医疗和手术转变之前都应接受关于生育力保存(FP)选项的咨询,但在实际中这似乎很少发生。以下综述是对PubMed、Medline和谷歌学术进行系统文献检索的结果,以确定当前和未来的FP选项、患者面临的治疗障碍、跨性别医疗服务提供者的实践模式,以及是否存在任何标准化的咨询方案。跨性别女性在其转变过程中的任何阶段,其选项从简单提供一份精液样本以供辅助生殖技术使用到涉及睾丸冷冻保存然后启动精子发生的实验技术。跨性别男性在开始激素治疗前后都可以采用任何适用于顺性别女性的辅助生殖技术。目前正在研究的未来选项包括卵巢组织冷冻保存(OTC)及卵母细胞成熟。除了就其FP选项进行咨询外,还应前瞻性地告知患者关于实现怀孕的要求、流程细节、相关的总费用,以及使用保存的遗传物质所固有的风险,包括失败风险以及对母婴健康的风险。跨性别患者表示使用辅助生殖服务很困难,原因是缺乏关于生育力的对话以及提供给他们的信息不足——大概是因为他们的情况不符合提供者熟悉的传统模式。医生和医疗服务提供者若能更好地了解情况,将有助于跨性别患者做出明智的决定,并更好地了解一般的跨性别患者以及他们可获得的FP选项。